Literature DB >> 15837753

Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival.

Eva Grafström1, Suzanne Egyházi, Ulrik Ringborg, Johan Hansson, Anton Platz.   

Abstract

PURPOSE: Both the retinoblastoma and p53 pathways are often genetically altered in human cancers and their complex regulation is in part mediated by the three gene products p16, p14(ARF), and p15 of the INK4 locus on chromosome 9p21. Partial or complete biallelic deletions of the INK4 locus have been recognized in a variety of malignant tumors, including malignant melanoma. We have in the present study measured the frequency of INK4 deletions in a large number of melanoma metastases and determined their association with clinicopathologic variables and survival data. EXPERIMENTAL
DESIGN: Quantitative real-time PCR, as well as fluorescence-based fragment analysis, has been used to perform measurements of the relative allelic concentrations of the INK4 genes in 112 human melanoma tumor samples from 86 patients.
RESULTS: Thirty-eight of 86 melanoma patients (44%) had metastases with biallelic losses in INK4. Ten of 20 patients with multiple metastases showed similar deletion patterns in all analyzed tumors. There was no significant association between any of the clinicopathologic variables and loss of INK4. However, loss of INK4 had an adverse effect on median survival from time of diagnosis. Patients with tumors with diploid INK4 had a median survival of 142 months, whereas those with monoallelic or biallelic loss in INK4 had a median survival of only 47 months (P = 0.006).
CONCLUSIONS: Our results point to homozygous deletions in the INK4 region as being one of the most common genetic alterations in malignant cutaneous melanoma. INK4 deletions are associated with an adverse prognosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15837753     DOI: 10.1158/1078-0432.CCR-04-1731

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

1.  Similar nucleotide excision repair capacity in melanocytes and melanoma cells.

Authors:  Shobhan Gaddameedhi; Michael G Kemp; Joyce T Reardon; Janiel M Shields; Stephanie L Smith-Roe; William K Kaufmann; Aziz Sancar
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

2.  Increased C-MYC copy numbers on the background of CDKN2A loss is associated with improved survival in nodular melanoma.

Authors:  Denitsa Koynova; Ekaterina Jordanova; Nicole Kukutsch; Pieter van der Velden; Draga Toncheva; Nelleke Gruis
Journal:  J Cancer Res Clin Oncol       Date:  2006-09-15       Impact factor: 4.553

3.  Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  World J Clin Oncol       Date:  2012-03-10

4.  Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion.

Authors:  Christopher R McEvoy; Huiling Xu; Kortnye Smith; Dariush Etemadmoghadam; Huei San Leong; David Y Choong; David J Byrne; Amir Iravani; Sophie Beck; Linda Mileshkin; Richard W Tothill; David D Bowtell; Bindi M Bates; Violeta Nastevski; Judy Browning; Anthony H Bell; Chloe Khoo; Jayesh Desai; Andrew P Fellowes; Stephen B Fox; Owen Wj Prall
Journal:  J Clin Invest       Date:  2019-03-05       Impact factor: 14.808

5.  A primary melanoma and its asynchronous metastasis highlight the role of BRAF, CDKN2A, and TERT.

Authors:  Gregory A Hosler; Teresa Davoli; Ilgen Mender; Brandon Litzner; Jaehyuk Choi; Payal Kapur; Jerry W Shay; Richard C Wang
Journal:  J Cutan Pathol       Date:  2014-12-11       Impact factor: 1.587

6.  DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations.

Authors:  Diego M Marzese; Richard A Scolyer; Maria Roqué; Laura M Vargas-Roig; Jamie L Huynh; James S Wilmott; Rajmohan Murali; Michael E Buckland; Garni Barkhoudarian; John F Thompson; Donald L Morton; Daniel F Kelly; Dave S B Hoon
Journal:  Neuro Oncol       Date:  2014-06-26       Impact factor: 12.300

7.  Mutational analysis of CDKN2A gene in a group of 390 larynx cancer patients.

Authors:  Katarzyna Kiwerska; Małgorzata Rydzanicz; Andrzej Kram; Martyna Pastok; Agata Antkowiak; Wenancjusz Domagała; Krzysztof Szyfter
Journal:  Mol Biol Rep       Date:  2009-08-19       Impact factor: 2.316

8.  Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.

Authors:  Anton Platz; Suzanne Egyhazi; Ulrik Ringborg; Johan Hansson
Journal:  Mol Oncol       Date:  2007-12-28       Impact factor: 6.603

9.  Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression.

Authors:  William K Kaufmann; Kathleen R Nevis; Pingping Qu; Joseph G Ibrahim; Tong Zhou; Yingchun Zhou; Dennis A Simpson; Jennifer Helms-Deaton; Marila Cordeiro-Stone; Dominic T Moore; Nancy E Thomas; Honglin Hao; Zhi Liu; Janiel M Shields; Glynis A Scott; Norman E Sharpless
Journal:  J Invest Dermatol       Date:  2007-06-28       Impact factor: 8.551

Review 10.  Recent advances on skin-resident stem/progenitor cell functions in skin regeneration, aging and cancers and novel anti-aging and cancer therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  J Cell Mol Med       Date:  2009-09-01       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.